Researchers discover first-ever link between tiny genetic structures, imminent heart attack risk
Researchers at the Intermountain Medical Center Heart Institute have, for the first time ever, made a connection between tiny genetic molecules called microRNAs and the imminent threat of a heart attack, according to a new study.
The findings are an important first step toward developing a method for predicting heart attacks in people who show no outward signs, but may be at great risk of having a heart attack. The research group will present study results today (March 25) at the American College of Cardiology's 61st Annual Scientific Session in Chicago.
"About half of all heart attacks occur in patients with no previous signs of heart disease. The heart attack is a surprise, and very often it's deadly," says Jeffrey L. Anderson, MD, chief of cardiovascular research at the Intermountain Medical Center Heart Institute and one of the study's authors. "This project has a lot of promise in helping us develop a way to identify these patients who don't show any obvious signs but are at imminent risk of suffering a heart attack."
The research group from Intermountain Medical Center, the flagship facility for the Intermountain Healthcare system, examined blood samples for the presence of six microRNA molecules that had previously been identified in patients after a heart attack. These genetic structures serve as an "on-off switch" for regulating the expression of a host of genes. When their levels drop, the genes they help to control are no longer regulated and can go "rogue."
The blood samples came from 85 patients who were sorted into four groups:
- Pre-heart attack patients, whose blood was drawn one to seven days before a heart attack
- Post-heart attack patients, whose blood was drawn within 36 hours after a heart attack
- Patients with cardiac problems, but no heart attack within one year before or after blood sample collection
- Healthy patients with no cardiac problems
The researchers believe the low levels of microRNA and the resulting genetic dysfunction may herald the heart attack. The three microRNAs are known as miR-122, miR-145, and miR-375.
"We don't know exactly which genes are controlled by these microRNAs, but this study gives us a good starting point for looking more deeply into the ways they influence the heart," says John Carlquist, PhD, director of Intermountain Healthcare's Cardiovascular Molecular and Genetic Laboratory at LDS Hospital and one of the study's authors.
The researchers envision a day in the not-too-distant future when a patient with cardiac risk factors does regular blood testing to watch for signs of imminent heart attack. Developments in nanotechnology one day may make it possible to continuously monitor an individual's blood for changes in these markers and alert a physician at any sign of danger.
The group says this study was possible only at Intermountain Healthcare, which helped to pioneer computerized health data collection in the 1950s and continues today. Intermountain is home to the world's largest cardiovascular DNA and plasma bank repository, which includes samples from more than 20,000 consenting patients. Combining these resources allowed researchers to search medical records for patients who had a heart attack and also had a frozen blood sample in storage that was drawn in the days before the heart attack.
"Because of this trove of patient records and specimens, we're uniquely equipped to do a study like this," says Dr. Carlquist.
The group will continue their research into microRNAs and heart attack with another study looking at a larger sample of patients, says Dr. Galenko.
Provided by Intermountain Medical Center
- Tiny heart pump helps heart attack, heart failure patients Mar 25, 2011 | not rated yet | 0
- Study: New risk score tool more accurately predicts patients' risk for cardiac disease and death Mar 14, 2010 | not rated yet | 0
- Possible new blood test to diagnose heart attacks Sep 20, 2011 | not rated yet | 0
- A 'guardian angel' to watch over your heart Apr 26, 2011 | not rated yet | 0
- Heart attacks are more serious in the morning: study Apr 26, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
The Durability of Bone: Long Falls
3 hours ago I am doing a paper on the physics in Valve's Portal and got interested in the "Long Fall Boots" that prevent any damage no matter how far you fall. I...
Is energy convertible to matter?
4 hours ago Can we convert energy to matter?
Rotating electron as a dipole is this right?
7 hours ago An electron as shown by the Stern Gerlach experiment behaves like a dipole (albeit only in one of two states). I have been trying to figure out how...
Dipole term in multipole expansion
11 hours ago Hi. I'm having some difficult in understanding something about the dipole term in a multipole expansion. Griffiths writes the expansion as a sum of...
Bubbles in a Pre-Boiling/Boiling pot of water
12 hours ago How is it that bubbles form on the bottom of a surface of a pot of boiling water? I think that there is probably an elementary answer to this...
Assumptions of Griffith's fracture theory
22 hours ago Any experts on Griffith's fracture theory? I am studying the subject and I am having hard time finding out if the theory is valid for all possible...
- More from Physics Forums - Classical Physics
More news stories
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Cardiology 7 hours ago | not rated yet | 0
One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...
Cardiology 7 hours ago | not rated yet | 0
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
Cardiology 8 hours ago | 5 / 5 (1) | 0 |
(Medical Xpress)—In a recent subgroup analysis of the largest blood pressure treatment trial in history, University of Alabama at Birmingham (UAB) researchers found that women and men react the same to ...
Cardiology 16 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
13 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
11 hours ago | 4.9 / 5 (9) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
6 hours ago | 3 / 5 (2) | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
7 hours ago | 5 / 5 (3) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
13 hours ago | 4.5 / 5 (6) | 0 |
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
10 hours ago | 5 / 5 (4) | 0 |